---
layout: default
title: Aluminum Oxide Bryonia Alba Root Horse Chestnut Ma
parent: Model Prediction Only (L5)
nav_order: 298
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Bryonia Alba Root Horse Chestnut Ma
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Polyherbal-mineral Compound: Insufficient Data, Drug Repurposing Prediction Not Generated

## One-Sentence Summary

The candidate drug is a polyformulation containing eight ingredients, including plant extracts (Bryonia alba, Horse Chestnut, Strychnos nux-vomica) and multiple mineral compounds. It currently has no drug approval registrations in Taiwan. The TxGNN model was unable to generate any drug repurposing prediction results because it could not match to a DrugBank ID and the original indication was missing. Before obtaining complete ingredient data and establishing clear pharmacological classification, this candidate case cannot enter the standard evaluation workflow.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No record |
| Predicted New Indication | None (TxGNN unable to generate prediction) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction unavailable) |
| Taiwan Market Status | ✗ Not marketed (no approvals) |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Possible

This polyformulation is composed of eight ingredients, including herbal medicines (Bryonia alba, Horse Chestnut, Strychnos nux-vomica seed) and mineral excipients (Aluminum Oxide, Magnesium Carbonate, Magnesium Chloride, Potassium Alum, Silicon Dioxide). Such formulations are commonly found in homeopathic products, where component concentrations and activity are typically far below conventional pharmacological doses.

The TxGNN model's predictions depend on a single DrugBank ID serving as a graph node; polyformulations cannot be represented as a single node in the knowledge graph, preventing the model from executing graph neural network inference. Furthermore, querying the Taiwan TFDA database yielded zero approval records, and no original indication is available for comparison; both critical inputs are missing.

If further assessment is needed, it is recommended to first deconstruct major ingredients with known pharmacological mechanisms—such as Horse Chestnut (Aesculus hippocastanum, active ingredient Aescin, DrugBank DB01122) and Strychnos nux-vomica—into individual single-component evaluations, and then integrate the polyformulation synergistic effect analysis.

---

## Clinical Trial Evidence

Currently no relevant clinical trial data available for presentation.

> This compound combination was not found in a corresponding registered trial on ClinicalTrials.gov. Individual components (such as Horse Chestnut Seed Extract for chronic venous insufficiency) have separate trial data, but these do not apply to the overall evaluation of this polyformulation.

---

## Literature Evidence

Currently no directly applicable literature data for the polyformulation.

> Literature on individual ingredients (such as Aescin for venous edema, Magnesium supplementation) does not represent the overall efficacy of this polyformulation and is not included in this table.

---

## Taiwan Market Information

This polyformulation has no drug approval registrations in the Taiwan TFDA database.

| Query Source | Query Status | Number of Approvals | Remarks |
|---------|---------|---------|------|
| TFDA | Queried (2026-03-24) | 0 | No matching records |

---

## Safety Considerations

Please consult the package inserts of individual components and homeopathic product instructions for safety information.

> **Special Note**: Strychnos nux-vomica contains the alkaloid Strychnine, which is neurotoxic at high doses. It is necessary to confirm that the dosage in this product complies with homeopathic extreme dilution standards and is not subject to conventional pharmacological toxicity assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This polyformulation lacks DrugBank ID correspondence, has no original indication record, has no approvals in Taiwan, and the TxGNN model failed to generate any prediction results; available data is insufficient to support any drug repurposing assessment.

**To proceed, the following is needed:**

- **Component deconstruction**: Confirm the dosage and dilution factors of each component in this formulation, and determine whether conventional pharmacological assessment or homeopathic framework is applicable

- **Primary component selection**: Select 1–2 components with known pharmacological mechanisms (recommend Horse Chestnut / Aescin), and resubmit to TxGNN for single-component prediction

- **DrugBank correspondence**: Query corresponding DrugBank IDs for each herbal component (Horse Chestnut → DB01122 Aescin, Nux vomica → DB01392 Brucine/Strychnine)

- **Toxicity confirmation**: Clarify the dilution level of Strychnos nux-vomica in this product, and only proceed with subsequent safety assessment after ruling out Strychnine toxicity concerns

- **Obtain manufacturer data**: If this product is a known marketed homeopathic product, obtain the manufacturer's package insert to confirm the original indication

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

